No Overall Survival Benefit for ¹⁷⁷Lu-Dotatate in Neuroendocrine Tumors

Gastrointestinal neuroendocrine tumors are rare and heterogeneous, with clinical behavior ranging from slow growing and indolent to rapidly progressive and virulent. Most such tumors express cell surface somatostatin receptors which can be targeted with somatostatin analogues.

Investigators now report final survival results from the NETTER-1 trial, an industry-sponsored, open-label, randomized phase 3 trial comparing treatment with lutetium 177 (¹⁷⁷Lu)-Dotatate (a radiolabeled somatostatin analogue) combined with long-acting octreotide (30 mg) to high-dose long-acting octreotide (60 mg). The trial enrolled 231 patients with midgut neuroendocrine tumors that had progressed on prior therapy with fixed-dose long-acting octreotide. The investiga…